The DCI Proteomics Shared Resource was designed to provide qualitative and quantitative proteomic support using nanoscale ultraperformance liquid chromatographs (single or multidimensional) coupled to high- resolution accurate-mass tandem mass spectrometers (LC/LC/MS/MS). While the Facility is available for use by the entire Duke research community, DCI members have priority access and are the first invited to participate in the Facility's significant early-access technology development projects. These projects are a direct result of close working relationships between the Proteomics Facility and instrument/software/reagent companies. As just one example, the Proteomics Facility is a formal Center of Innovation for Waters Corporation, the manufacturer of the majority of our LC and MS tools. These industry relationships are integral to the Proteomics Facility's ability to provide affordable emerging technologies to answer innovative research questions relevant to DCI members. The Proteomics Facility utilizes ~$4M of state-of-the-art proteomic instrumentation for basic science experiments and clinical studies (including biomarker discovery and biomarker verification). Facility policy initiates all potential projects with an on-site consultation with PhD-level Facility staff to enable collaborative creation of custom experimental designs that meet the researcher's scientific needs. The Facility uses a custom, state of the art LIMS for secure electronic sample submission and data return. The Facility's operating budget is supported by the Cancer Center Support Grant, the Duke Translational Research Institute (DTRI), and user chargebacks, the last of which accounts for the vast majority of our budget. Our annual cost-effectiveness survey shows that our user fees, which reflect actual costs, are at or lower than other academic proteomics facilities. In calendar year 2012, the Facility served 90 investigators, 27 of whom were DCI members. Use of the Resource contributed to 36 DCI publications during the funding period. The long-term objectives of the Proteomics Core Facility/Shared Resource are (1) to continue to provide the highest quality, cost-effective, full-service proteomics expertise and analyses to the Duke research community, with priority given to DCI members, and (2) to continue testing and, when appropriate, implementing emerging proteomic and mass spectrometry technologies through our relationships with industry partners and with the involvement of DCI researchers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-44
Application #
9404302
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-01-01
Budget End
2018-12-31
Support Year
44
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784
Dai, Ziwei; Mentch, Samantha J; Gao, Xia et al. (2018) Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun 9:1955

Showing the most recent 10 out of 513 publications